Nitric Oxide

Nitric Oxide (NO)

• Objectives:

  • Understand the physiology and clinical application of NO.

  • Effects on vascular tone.

  • Binding with hemoglobin.

  • Indications and dosages.

  • Nursing care plan formulation and complications.

• Introduction:

  • Endogenous NO is released by endothelial cells, crucial in cardiovascular, immune, and nervous systems.

  • Present in expired breath at < 50 parts per billion.

  • NO is colorless, odorless, and a gaseous free radical with high diffusibility.

  • Therapeutic use aimed at pulmonary disorders and right-sided heart dysfunction.

Biology and Physiology of NO

• Production:

  • Synthesized from L-arginine by NO synthase.

  • Causes vascular smooth muscle relaxation by increasing cGMP levels, decreasing intracellular calcium.

  • Similar effects are seen with nitroglycerin and nitroprusside.

• Clearly Defined Mechanism:

  • NO quickly binds with hemoglobin to form nitrosylhemoglobin; has a greater affinity for hemoglobin than oxygen.

  • Rapid inactivation leads to a short half-life (3-10 seconds), minimizing systemic effects like blood pressure changes.

Physiology of Pulmonary Diseases and Inhalation of NO

• Pulmonary Hypertension:

  • Resulting from endothelial cell damage in the pulmonary vasculature.

  • High pulmonary artery pressure (PAP), increased pulmonary vascular resistance (PVR), and mixed ventilation/perfusion (V/Q) can occur.

  • Hypoxic pulmonary vasoconstriction diverts blood flow to better-ventilated lung areas.

• Inhaled NO Benefits:

  • Selective pulmonary vasodilation with minimal systemic effects.

  • Reduces PAP, improves right ventricular (RV) function, and enhances gas exchange by redistributing blood flow.

  • Enhances arterial oxygen partial pressure (PaO2).

• Indications for NO:

  • Treatments for conditions like pulmonary hypertension, right heart failure post-transplant, lung transplant candidates with severe pulmonary hypertension, adult respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease (COPD).

Dosage and Administration

• Common inhaled dosage range: 2-80 parts per million (ppm).

  • Desired effects typically achieved at 10-40 ppm.

  • Important to use the lowest effective dose due to short-lived effects.

Complications Associated with NO Toxicity

1. Nitrate Toxicity:

   • Majority excreted through binding with hemoglobin; can lead to methemoglobin and nitrates, with potential adverse effects if inhaled at higher concentrations.

2. Methemoglobinemia:

   • May occur when methemoglobin levels exceed 2%, leading to decreased oxygen transport capability (functional anemia).

   • Symptoms: cyanosis without respiratory distress, tachycardia, confusion, and chocolate-brown urine.

3. Rebound Pulmonary Hypertension:

   • Prolonged inhalation may decrease endogenous NO production; abrupt cessation can precipitate severe complications.

4. Effects on Platelet Function:

   • NO inhibits platelet aggregation, thus bleeding risks are minimal.

5. Immunosuppression:

   • Potential increased risk for infections due to NO's immunosuppressive properties.

Nursing and Respiratory Therapy Care

• Monitoring:

  • Vital signs every hour, including blood pressure (BP), central venous pressure (CVP), and oxygen saturation.

  • Assess pulmonary artery pressures (PAP) and adjust NO dosages as necessary.

  • Monitor methemoglobin levels before NO treatment and hourly thereafter.

  • Document NO/NO2 levels regularly.

Epoprostenol (Caripul)

• Overview:

  • Epoprostenol (previously Flolan) is effective for life prolongation in severe pulmonary arterial hypertension (PAH).

  • It acts as a potent vasodilator and is a natural form of prostacyclin, vital for vascular relaxation.

  • Used primarily to assess vascular reactivity in patients awaiting heart transplants.

• Benefits Compared to NO:

  • Less expensive and no toxic metabolites or complicated delivery requirements.

• Side Effects:

  • Commonly reported: facial flushing, gastrointestinal distress, and potential headaches.